Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …

This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

We read with interest the manuscript “Sensitivity and specificity of surveillance case
definitions in detection of influenza and respiratory syncytial virus among hospitalized …

GS-441524, an RNA‐dependent RNA polymerase (RdRp) inhibitor, is a 1′-CN-substituted
adenine C-nucleoside analog with broad-spectrum antiviral activity. However, the low oral …

Therapeutic options against SARS-CoV-2 are underutilized. Two oral drugs, molnupiravir
and paxlovid (nirmatrelvir/ritonavir), have received emergency use authorization. Initial trials …

Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …

Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …

In a pivotal trial (EPIC-HR), a 5-day course of oral ritonavir-boosted nirmatrelvir, given early
during symptomatic SARS-CoV-2 infection (within three days of symptoms onset) …

Background Some patients with systemic autoimmune rheumatic disease and
immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS …